Blueprint Medicines Corp - COM (BPMC)

Historical Portfolio Holders from Q2 2015 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / COM
Shares, excl. options Q2 2024
66.1M
Holdings value Q2 2024
$7.13B
Value change Q2 2024
+$112M
Grand Portfolio weight change Q2 2024
+0%
Number of holders
299
Number of buys Q2 2024
130
Number of sells Q2 2024
-86
Average buys Q2 2024 %
+0.002%
Average sells Q2 2024 %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 34.3M $3.17B -$66.8M $92.50 195
2024 Q2 66.1M $7.13B +$112M $107.78 305
2024 Q1 65M $6.17B +$115M $94.86 280
2023 Q4 64M $5.9B +$1.82M $92.24 256
2023 Q3 64.1M $3.22B -$22.6M $50.22 215
2023 Q2 63.6M $4.02B +$55M $63.20 217
2023 Q1 63.3M $2.84B +$37.4M $44.99 212
2022 Q4 62.6M $2.74B -$81.1M $43.81 217
2022 Q3 62.9M $4.14B -$131M $65.89 223
2022 Q2 63.1M $3.19B +$153M $50.51 218
2022 Q1 59.8M $3.82B -$48.8M $63.88 231
2021 Q4 58.9M $6.31B -$30.9M $107.11 268
2021 Q3 59.6M $6.13B +$117M $102.81 277
2021 Q2 58.4M $5.14B -$35.1M $87.96 269
2021 Q1 58.5M $5.69B +$111M $97.23 254
2020 Q4 57.6M $6.46B +$71.8M $112.15 270
2020 Q3 56.8M $5.27B +$134M $92.70 232
2020 Q2 56.2M $4.38B +$150M $78.00 225
2020 Q1 54.5M $3.18B +$194M $58.48 204
2019 Q4 50.7M $4.06B -$62.8M $80.11 224
2019 Q3 51.4M $3.78B +$140M $73.47 215
2019 Q2 49.5M $4.67B +$324M $94.33 218
2019 Q1 48.5M $3.88B +$227M $80.05 200
2018 Q4 45.6M $2.46B -$75.5M $53.91 157
2018 Q3 44.9M $3.5B +$29M $78.06 189
2018 Q2 44.8M $2.84B +$140M $63.48 178
2018 Q1 41.2M $3.78B +$79.7M $91.70 175
2017 Q4 42.8M $3.23B +$311M $75.41 167
2017 Q3 36.3M $2.53B +$47.5M $69.67 137
2017 Q2 35.9M $1.81B +$83.9M $50.67 123
2017 Q1 34.7M $1.38B +$410M $39.99 133
2016 Q4 26M $730M +$172M $28.05 102
2016 Q3 19.2M $569M +$16.3M $29.70 86
2016 Q2 19.5M $395M +$32.9M $20.25 81
2016 Q1 17.9M $323M -$4.07M $18.05 71
2015 Q4 18M $474M +$22.1M $26.34 74
2015 Q3 23.8M $508M +$14.5M $21.34 69
2015 Q2 23.2M $611M +$610M $26.49 69